Ekaterini Boleti - Publications

Corrigendum to "Long-term real-world survival outcomes with dual immune checkpoint blockade in synchronous metastatic renal cell carcinoma: implications for the design of prospective cytoreductive nephrectomy trials" [Eur. Urol. Open Sci. 83 (2026) 133-141].

Journal: European urology open science

Published: June 17, 2026

Fumarate hydratase-deficient renal cell carcinoma - results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment.

Journal: Cancer treatment and research communications

Published: May 03, 2026

Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 21, 2026

Long-term Real-world Survival Outcomes with Dual Immune Checkpoint Blockade in Synchronous Metastatic Renal Cell Carcinoma: Implications for the Design of Prospective Cytoreductive Nephrectomy Trials.

Journal: European urology open science

Published: December 05, 2025

Loss of ARID1A expression is associated with worse survival and reduced tumor infiltrating lymphocytes in advanced clear cell renal cell carcinoma.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: August 03, 2025

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 17, 2025

A decade long insight into patient views on kidney cancer care delivery.

Journal: BJU international

Published: September 12, 2024

Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx.

Journal: Nature

Published: July 04, 2024

Renal mass biopsy - a practical and clinicopathologically relevant approach to diagnosis.

Journal: Nature reviews. Urology

Published: May 09, 2024

Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: November 06, 2023

Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease?

Journal: European urology open science

Published: July 13, 2023

Case Report: Disease progression of renal cell carcinoma containing a novel putative pathogenic KAT6A::NRG1 fusion on Ipilimumab- Nivolumab immunotherapy. A case study and review of the literature.

Journal: Frontiers in oncology

Published: November 30, 2022